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Intention
• Seek First to Understand, Then to be Understood (Habit #5)
• Begin with the End in Mind (Habit #2)
The 7 Habits of Highly Effective People ~ Stephen Covey
This reference guide was created to provide understanding of basic statistical
concepts used in clinical research to equip you with the skills necessary to
succeed in this area including effective collaborations with statisticians.
The overall objectives of the reference guide are:
• To introduce or review concepts to consider when designing a clinical trial;
• To introduce or review the four phases of clinical trials including different
types of designs for Phase I and Phase II clinical trials;
• To introduce or review observational studies;
• To introduce or review analysis of categorical, continuous, and time-toevent measures as well as Bayesian methodology.

Thank you for participating in this clinical research workshop and we wish you
much success in your careers.
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I.

II.

III.

IV.
V.

VI.

Protocol Development
a. Prospective Studies (concepts to think about when designing a clinical trial/writing a
protocol)
i. Disease to be treated/trial entry criteria.
ii. Treatments/doses/schedules/treatment combinations.
iii. Main goal(s) of the trial (i.e., how trial results may be used for planning future
studies or changing clinical practice).
iv. Main clinical outcome(s).
v. Secondary goals.
vi. Anticipated accrual rates/sample size.
b. Observational Studies
c. Common Efficacy Endpoints - Definitions
d. Sample Size/Power Determination
Clinical Trial Designs
a. Phase I Dose Finding
i. Ruled-based designs
ii. Model-based designs
iii. Model-assisted designs
b. Phase II Single Arm Binary
i. N-stage group sequential designs
ii. Model-based designs
c. Phase III Registration
d. Phase IV Post Marketing
e. Pilot Studies
Observational Studies
a. Cohort Studies
b. Case-Control Studies
c. Cross-Sectional Studies
Data quality
Statistical methodology
a. Analysis of Categorical Measures
i. Fisher’s exact test/chi-squared test
ii. Logistic regression
b. Analysis of Continuous Measures
i. Parametric (e.g., t-test)/non-parametric (e.g., Wilcoxon rank-sum test)
ii. Linear regression
c. Analysis of Time-to-event/survival Measures
i. Kaplan-Meier method
ii. Cox proportional hazards regression
iii. Competing risks
d. Bayesian methods (basic concept)
Miscellaneous (p-values, confidence intervals, multivariate vs. multivariable)
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PROTOCOL DEVELOPMENT
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1. Protocol Development
Clinical research provides the foundation for the practice of medicine. Ideally, the principles of medical
practice should be based on sound scientific rationale and evidence. Clinical studies are useful to the extent
that they yield valid inferences. The goal of proper study design is to minimize the errors that threaten the
scientific validity of conclusions based on these inferences.
1.1.

Prospective Studies

Well-conducted randomized controlled trials, with adequate numbers of subjects; blinding of therapies,
subjects and researchers; and carefully standardized methods of measurement and analysis are the best
evidence for a cause-and-effect relationship.
The protocol is a document that describes how a clinical trial will be conducted and ensures the safety of the
trial subjects and integrity of the data collected. Protocols should be clear, unambiguous and maintain
scientific integrity. The protocol should describe the background, rationale, objectives, design, methodology,
statistical considerations, and organization of a clinical study.
Some concepts to think about when designing a clinical trial/writing a protocol:
1. Main Goal(s) of the Trial
a. How the trial results may be used for planning future studies or changing clinical practice.
b. What are the primary objective(s) and endpoint(s) (i.e., what is the primary question you
would like the study to address)?
2. Other Goals of the Trial
a. What are the secondary and exploratory objectives and endpoints?
3. Study Design
a. What is the best study design to address the study objectives?
b. What disease group(s) are of interest (inclusion/exclusion criteria)?
c. What treatments/doses/schedules/combinations will be investigated (best control group for
study population)?
d. How many visits are required?
e. What assessments will be administered at each visit?
f. How many subjects are needed to address the primary objective/how many are
possible based on funding?
g. How many sites will be participating?
h. What’s the anticipated accrual rate?
4. How will the data be collected?
a. Excel, REDCap, Prometheus, DMI, MOCLIP
1.2.

Observational Studies

Studies that do not use random assignment to allocate subjects into comparative groups are collectively
referred to as non-experimental or observational studies. Observational studies are also non-interventional,
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meaning the treatment and care of the subject are not influenced by the study but are conducted as in usual
practice. These studies reflect less artificial and more naturalistic circumstances; people’s lives and
behaviors are not being modified by restrictive rules or specific recommendations, and the natural history of
disease occurrence and progression can be better observed. As such, observational studies may provide
opportunities to evaluate the effectiveness of treatment in people who are more like those who are in need
of treatment in the community (i.e., more generalizable). Similar to clinical trials, protocols for observational
studies should be clear, unambiguous and maintain scientific integrity. The protocol should describe the
background, rationale, objectives, methodology, and statistical considerations for the study.
1. Main Question the Study will Address
a. What disease group(s) are of interest?
b. How the study results may be used for planning future studies or changing clinical practice.
c. What are the primary objective(s) and endpoint(s)?
2. Other Goals of the Study
a. What are the secondary and exploratory objectives and endpoints?
3. Sample Size Determination
4. Statistical Methodology
a. Addressing potential biases
1.3.

Study Objectives vs. Endpoints

The objective of a study is an active statement about how the study will address
specific research question(s). For example, a primary objective of a study could be to compare the efficacy
of Drug X to Drug Y in subjects diagnosed with multiple myeloma. There could be many endpoints for this
objective, including overall survival, progression-free survival or objective response rate. An endpoint is not
an objective but can be included in the objective; the primary objective of the study is to compare overall
survival of Drug X to Drug Y in subjects diagnosed with multiple myeloma.
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1.4.

Common Efficacy Endpoints

Endpoints

Definition

Advantages

Limitations

•

•

Overall
survival (OS)

Time from
randomization/start of
treatment until death
from any cause

•

Universally
accepted
measure of
direct benefit
Easily and
precisely
measured

•

•

Progressionfree survival
(PFS)

Time from
randomization/start of
treatment until disease
progression or death

•

•

Time to
progression
(TTP)

Recurrencefree survival
(RFS)

Time from
randomization/start of
treatment until objective
tumor progression; does
not include deaths

Time from date of
response to the first of
either recurrence or
relapse, second cancer,
or death

•

•

•

Requires small
sample size
and shorter
follow-up time
compared with
OS
Includes
measurement of
stable disease
(SD)
Not affected by
crossover or
subsequent
therapies
Generally based
on objective and
quantitative
assessment

Similar to PFS;
may be useful in
evaluation of
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•

•

•
•

•

•

May require a
larger trial
population and
longer follow-up to
show statistical
difference between
groups
May be affected by
crossover or
subsequent
therapies
Includes deaths
unrelated to cancer

Validation as a
surrogate for
survival can be
difficult in some
treatment settings
Not precisely
measured (i.e.,
measurement may
be subject to bias)
Definition may vary
among trials
Requires frequent
radiologic or other
assessments
Requires balanced
timing of
assessment
among treatment
arms

Similar to PFS

highly toxic
therapies

Objective
response rate
(ORR)

Duration of
response
(DoR)

Proportion of subjects
with reduction in tumor
burden of a predefined
amount (typically
includes complete
remission and partial
response)

Time from
documentation of tumor
response to disease
progression

•

•

•

Can be
assessed in
single-arm trials
Requires a
smaller
population and
can be assessed
earlier,
compared with
survival trials
Effect is
attributable
directly to the
drug, not the
natural history of
the disease

•

Not a
comprehensive
measure of drug
activity

1.5. Sample Size/Power Determination
The field of statistics exists because it is usually impossible to collect data from all individuals of interest
(population). Thus, the only solution is to collect data from a subset (sample) of the individuals of interest,
but the real desire is to know the “truth” about the population. It is imperative in medical research to ensure
that reported comparisons are based on a sufficient number of subjects to be statistically valid. Small
samples may lack sufficient statistical power to detect important differences or associations.
1.5.1. Hypothesis Testing
Hypothesis testing is a process in statistics whereby an assumption regarding a population parameter is
tested. Hypothesis testing is used to assess the plausibility of a hypothesis (i.e., assumption) by using
sample data. In hypothesis testing, there are the null hypothesis (H0) and the alternative hypothesis (H1
or Ha). The null hypothesis is usually a hypothesis of equality between population parameters (e.g., there
is no difference in response rate between the experimental treatment and standard of care). The
alternative hypothesis is effectively the opposite of a null hypothesis (e.g., the response rate in the
experimental treatment is higher than the standard of care). Thus, they are mutually exclusive, and only
one can be true.
The following table presents a 2x2 representation of the truth from the population and the decision based
on the study sample. The significance (α) level is the probability that the decision based on the study
sample is that there is a difference when in fact there is no difference. Whereas, the power is the
probability that the decision based on the sample correctly concludes there is a difference.
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TRUTH (population)

DECISION (based on study sample)
There is no difference
There is a difference

There is no difference
(H0)
There is a difference
(Ha)

Significance (α) level
Power

A scientific conclusion is always drawn from the statistical testing of hypothesis, in which the chosen
significance (α) level, is used for decision-making. However, the probability of committing false statistical
inferences is considerably increased when more than one hypothesis is simultaneously tested, which
therefore requires proper adjustment of the significance level.
Examples
If the primary objective of your study is to test if an experimental drug is superior to the standard of care or
a historical control, the sample size/power computation required will be based on hypothesis testing.
Information required for sample size/power computations includes:
a. The number of groups (e.g., one: experimental vs. historical control; two: experimental vs. active
control [e.g., standard of care]).
• Obtained from the study design.
b. Parameter estimates for each group (e.g., response rates, change in tumor size, standard deviation
of tumor size, effect size [i.e., the absolute value of difference between group means divided by the
common standard deviation], median survival or survival rates).
• Primary objective endpoint(s) obtained from the primary study objective. Estimates are
obtained from literature or previous studies. Often, this information is unknown. In those
cases, use estimates that are considered to be clinically meaningful.
c. Significance level or α level (one-sided or two-sided).
• Typically 5%; one-sided or two-sided depends on whether your alternative hypothesis is
ORRA > ORRB (one-sided), ORRA < ORRB (one-sided), or ORRA ≠ ORRB (two-sided).
d. Power or sample size (depending on what is being computed)
• ≥ 80% power is common; although 70% is also acceptable for Phase II trials
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Example for one group vs. historical control for response rates:

Example for two groups for change in tumor size:
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Example for two groups for survival:

1.5.2 Estimation – Confidence Interval
If the primary objective of your study is to estimate a parameter, perhaps because this is a phase II study
with small sample sizes, then your sample size justification will be based on precision via a confidence
interval.
Information required for precision computations includes:
a. The number of groups (e.g., one: experimental vs. historical control; two: experimental vs. control).
• Obtained from the study design
b. Parameter estimates (e.g., proportion for binary, effect size for continuous)
c. Confidence interval (one-sided or two-sided).
• 95% is common; one-sided or two-sided
Example for one group for response rate:
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CLINICAL TRIAL DESIGNS
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A clinical trial is a planned prospective experiment involving human subjects from a specified population
designed to evaluate an intervention in order to determine appropriate interventions for future members
from the same population.
1.

Phase I (Dose Finding) Clinical Trials

The focus in phase I trials is looking at what the drug does to the body and what the body does with the
drug. Phase I trials aim to find the best dose of a new drug with the fewest side effects. These studies
also determine how a drug is absorbed, distributed, metabolized and excreted as well as the duration of
its action. Very low doses of the drug are given initially to subjects while higher doses are given to
subsequent subjects until side effects become too severe or the desired effect is seen. The number of
subjects included in phase I trials are typically small (e.g., 15 to 30). The drug may help subjects, but
phase I trials are to test a drug’s safety as opposed to efficacy. If a drug is found to be safe enough, it
can be tested in a phase II clinical trial.
A phase I trial design has many components, including starting dose, dose increment, dose escalation
method, number of subjects per dose level, specification of dose-limiting toxicities (DLT) and assessment
period, target toxicity level, definition of the maximum tolerated dose (MTD) and recommended dose for
phase II trials (RP2D).
Dose escalation methods for phase I cancer clinical trials fall into two broad classes: rule-based designs,
which include the traditional 3+3 design and its variations, and model-based designs. Rule-based designs
assign subjects to dose levels according to pre-specified rules based on actual observations of target
events (e.g., the DLT) from the clinical data. Typically, the MTD or RP2D is determined by the prespecified rules as well. On the other hand, the model-based designs assign subjects to dose levels and
define the RP2D based on the estimation of the target toxicity level by a model depicting the dose–toxicity
relationship.
1.1.

Algorithm (Rule)-Based Designs

Algorithm-based designs are a class of conventional designs that use a set of simple, prespecified rules
to determine the dose escalation and de-escalation. Examples include the conventional 3+3 design and
its extensions, such as the accelerated titration design and the rolling 6 design. The conventional 3+3
design remains the predominant method for conducting phase I cancer clinical trials. It requires no
modeling of the dose–toxicity curve beyond the classical assumption for cytotoxic drugs that toxicity
increases with dose. This algorithm-based design proceeds with cohorts of three subjects; the first cohort
is treated at a starting dose that is considered to be safe based on extrapolation from animal toxicological
data, and the subsequent cohorts are treated at increasing dose levels that have been fixed in advance.
The traditional 3+3 algorithm is described below.
•
•
•
•

Enroll 3 subjects at the starting dose level
If 0 of the 3 subjects experiences a DLT at a given dose level, proceed to the next higher dose
level with a cohort of 3 subjects
If 1 of 3 subjects experiences a DLT at a given dose level, enter 3 additional subjects at the current
dose level
If 1 of 6 subjects experiences a DLT at a given dose level, proceed to the next higher dose level
with a cohort of 3 subjects
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•
•
•

If at least 2 of 3 or 2 of 6 subjects experience a DLT at a given dose level, then the MTD has been
exceeded
Once the MTD has been exceeded, treat another 3 subjects at the previous dose level if there
were only 3 subjects treated at that dose level
The MTD is the highest dose level in which 6 subjects have been treated with at most 1
experiencing a DLT

The main advantages of algorithm-based methods are that they are easy to implement and do not require
special software. However, their performance (operating characteristics) is not guaranteed and they have
some drawbacks. For example, these designs may be inefficient in establishing the dose that meets a
specific target toxicity level. In addition, the decision of dose allocation for future subjects as well as the
definition of the RP2D rely on information from the current dose level and do not use all available
information. As such, the RP2D is then selected from the pre-specified dose levels depending on which
one best fits the definition of acceptable toxicity set a priori. However, although not ideal, the algorithmbased methods have been successful in establishing safe recommended doses for phase II trials during
the past several decades for anticancer agents that were eventually used worldwide in clinical practice.
1.2.

Model-Based Designs

An alternative dose escalation method for phase I clinical trials is to use statistical models that actively
seek a dose level that produces a prespecified probability of dose-limiting toxicity by using toxicity data
from all enrolled subjects to compute a more precise dose–toxicity curve. This method is typically carried
out using Bayesian models. Bayesian models require an initial estimation of DLT rate (also called prior
distribution of θ), which characterizes the shape of the dose–toxicity curve. The occurrence of toxicity (or
not) in subjects enrolled at each dose level provides additional information for the statistical model and
results in an adjustment of θ (i.e., posterior distribution of θ) according to Bayes’ theorem. The posterior
distribution is then evaluated to identify the dose closest to the target toxicity level, and this dose is used
to treat future subjects and to set the recommended dose for phase II trials. These model-based designs
use all of the available data to model the dose–toxicity curve, and they provide a confidence interval for
the RP2D at the end of the trial.
Some model-based designs include continual reassessment method (CRM; O'Quigley, J., Pepe, M.,
Fisher, L. Continual reassessment method: a practical design for phase I clinical trials in cancer.
Biometrics 1990; 46, 33-48) and EffTox method (Thall, Peter F., Cook, John D. Dose-Finding Based on
Efficacy-Toxicity Trade-Offs. Biometrics 2004; 60, 684-693).
1.3.

Model-Assisted Designs

Model-assisted designs were developed to combine the advantages of algorithm-based designs and
model-based designs (Yuan, Ying, Lee, Jack J., Hilsenbeck, Susan G. Model-Assisted Designs for
Early-Phase Clinical Trials: Simplicity Meets Superiority. JCO Precision Oncology 2019;3, 1-12). Similar
to the model-based design, the model-assisted design uses a statistical model (e.g., the binomial
model) to derive the design for efficient decision making; however, like the algorithm-based design, its
dose escalation and de-escalation rule can be predetermined before the onset of the trial and, thus, can
be implemented in as simple a way as the algorithm-based designs.
Some model-assisted designs include modified toxicity probability interval method (mTPI; Ji Y, Liu P, Li
Y, Bekele BN. A modified toxicity probability interval method for dose-finding trials. Clinical Trials 2010;
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7: 653-663) and Bayesian optimal interval (BOIN; Liu S. and Yuan, Y. Bayesian Optimal Interval Designs
for Phase I Clinical Trials. Journal of the Royal Statistical Society: Series C 2015; 64, 507-523).
1.3.1. Bayesian Optimal Interval (BOIN) Design (Example)
The BOIN design is implemented in a simple way similar to the traditional 3+3 design, but is more flexible
and possesses superior operating characteristics. In this example, the phase I trial explores 5 dose levels
and the maximally accepted DLT rate is 30%. A total of 15 subjects will be enrolled in cohorts of size 3
starting at the 2nd dose level.
The target toxicity rate for the MTD is 𝜙 = 0.3 and the maximum sample size is 15. We will enroll and
treat subjects in cohorts of size 3. To guide dose-escalation decisions, if the observed DLT rate at the
current dose is ≤ 0.236, the next cohort of subjects will be treated at the next higher dose level; if it is ≥
0.359, the next cohort of subjects will be treated at the next lower dose level. For the purpose of
overdose control, doses 𝑗 and higher levels will be eliminated from further examination if Pr(𝑝! > 0.3 |
data) > 0.95, where 𝑝! is the true DLT rate of dose level 𝑗, 𝑗 = 1,⋯, 5. When the lowest dose is
eliminated, stop the trial for safety. Figure 1 presents the dose escalation/de-escalation rules for the
study. Note that although subjects are enrolled in cohorts of size 3, Figure 1 includes decision rules for
all subjects (i.e., it is not necessary to wait for all of the subjects in the next cohort to complete the DLT
assessment period before making decisions for each enrolled subject). For example, if 4 subjects have
been enrolled in the trial with one subject experiencing a DLT, the decision for the next subject would
be to remain at the current dose level.
Figure 1. Dose escalation/de-escalation rules for the BOIN design
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After the trial is completed, select the MTD based on isotonic regression as specified in Liu and Yuan
(2015). This computation is implemented by the shiny app “BOIN” available at
http://www.trialdesign.org. Specifically, select as the MTD the dose for which the isotonic estimate of
the toxicity rate is closest to the target toxicity rate. If there are ties, select the higher dose level when
the isotonic estimate is lower than the target toxicity rate and select the lower dose level when the
isotonic estimate is greater than or equal to the target toxicity rate.
Operating Characteristics
Table 1 shows the operating characteristics of the trial design based on 1000 simulations of the trial
using shiny app “BOIN” available at http://www.trialdesign.org. The operating characteristics show that
the design selects the true MTD, if any, with high probability to the dose levels with the DLT rate closest
to the target of 0.3.
Table 1. Operating characteristics of the BOIN design
Dose
1

Dose
2

Dose
3

Dose
4

Dose
5

Scenario 1
True DLT
rate

0.01

0.05

0.1

0.2

0.3

Selection %

0

0.7

12.8

41.4

45.1

% Pts treated

0

24.1

30.0

29.4

16.5

Scenario 2
True DLT
rate

0.05

0.1

0.2

0.3

0.4

Selection %

0.4

10.8

30.4

39.6

18.8

% Pts treated
Scenario 3
True DLT
rate

1.0

31.8

36.2

23.7

7.3

0.1

0.2

0.3

0.4

0.5

Selection %
% Pts treated

6.3
6.4

31.1
44.5

36.1
33.8

22.9
13.6

3.6
1.8

True DLT
rate

0.2

0.3

0.4

0.5

0.6

Selection %

23.6

45.8

21.7

7.7

0.6

% Pts treated

17.3

52.0

24.5

5.6

0.6

Scenario 5
True DLT
rate

0.3

0.4

0.5

0.6

0.7

Selection %

46.0

35.8

9.6

1.7

0

Number of
Subjects

% Early
Stopping

0
15

0
15

0
15

Scenario 4
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0.6
15

6.9

% Pts treated

33.1

50.4

14.6

1.8

0.01

Scenario 6
True DLT
rate

0.5

0.6

0.7

0.8

0.9

Selection %

41.8

8.1

0.3

0

0

% Pts treated

55.7

40.8

3.4

0.1

0

14.7

49.8
12.7

Simulations have shown that model-based and model-assisted methods, which use all toxicity
information accumulated during the trial, achieve good estimations of the target probability of doselimiting toxicity at the RP2D without treating too many subjects at suboptimal doses. Some of the
challenges presented by some model-based designs include the need for biostatistical expertise and
available software on site to perform model fitting in real time, as well as an expedited collection of data
from each cohort of subjects to fit the model. As such, implementation of these designs may not be
straightforward. In addition, the model may fail to reach the RP2D if the prior distributions for the
parameters of the dose–toxicity curve are inadequate, or conversely, if the prior assumptions are
overbearing.
2. Phase II Clinical Trials
Phase II trials further assess safety as well as if a drug works. The drug is often tested among subjects
with a specific type of cancer. Phase II trials are done in larger groups of subjects compared to phase I
trials. Subjects are closely watched to see if the drug works. If a drug is found to work, it can be tested
and compared to the current (standard-of-care) drug in a phase III clinical trial.
Since the number of subjects included in phase I trials is typically small (e.g., 15 to 30) and the safety
profile of the drug is limited to a few subjects evaluated at the MTD/RP2D, many phase II trials include
formal toxicity and/or futility monitoring which will stop the trial early (i.e., before all subjects have been
enrolled) if the accumulated data indicate the likelihood of excessive toxicity is high and the likelihood of
acceptable efficacy is low, respectively.
2.1.

N-stage Group Sequential Designs

In an N-stage design, the subjects are enrolled in N stages with a binary endpoint. For a two-stage design,
at the completion of the first stage, an interim analysis is performed to determine if the second stage
should be conducted. The endpoint typically evaluated is response rate (responders vs. non-responders).
If the number of subjects responding is greater than a certain amount, the second stage is conducted.
Otherwise, it is not.
2.1.1. Simon’s Two-Stage Design (Example)
The primary objective of this example study is to assess the efficacy of Drug X in subjects with melanoma
and brain metastases. The primary endpoint is the ORR to this regimen defined as the percentage of
number of complete response or partial response in total number of subjects treated. The trial will be
conducted by the Simon's optimal two-stage design and the ORR will be estimated accordingly.
It is assumed that Drug X will have a target ORR of 35%. An ORR of 19% or lower is considered a failure
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and Drug X will be rejected under this circumstance. When the probability of accepting a 'bad' regimen
(i.e. ORR ≤ 19%) is 0.10 and the probability of rejecting a 'good' regimen (i.e. ORR ≥ 35%) is also 0.10,
Simon's design requires 23 subjects to enter in the first stage. If 4 or fewer subjects respond to the
treatment, the trial will be stopped and the regimen will be declared as ineffective. If there are 5 or more
responses, 34 more subjects will be entered in the study to reach a total of 57 subjects. At the end of the
study, Drug X will be rejected if ORR is less than or equal to 14/57 and will be accepted otherwise. The
operating characteristics of the trial are given as follows: When the true ORR is 0.19 the probability of
stopping the trial early is 55%. On the other hand, if the true ORR is 0.35, the probability to stop the trial
early is 6%. The expected sample sizes are 38.3 and 55.1 when the true ORRs are 0.19 and 0.35,
respectively.
This design has the optimal property of minimizing the expected sample size under the null hypothesis
that the new regimen is ineffective.
2.2.

Model-Based Designs

As in phase I designs, an alternative monitoring method for phase II clinical trials is to use statistical
models. Some model-based designs include methods by Thall et. al. (Thall PF, Simon RM, Estey EH.
Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Statistics in
Medicine 1995; 14:357-79 and Thall, PF and Sung, H-G. Some extensions and applications of a Bayesian
strategy for monitoring multiple outcomes in clinical trials. Statistics in Medicine 1998; 17:1563-1580),
Bayesian predictive probability method (Lee JJ, Liu DD. A predictive probability design for phase II cancer
clinical trials. Clinical Trials 2008; 5(2):93-106), and Bayesian optimal phase 2 (BOP2; Zhou, H., Lee, J.
J., & Yuan, Y. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex
endpoints. Statistics in Medicine 2017; 36(21):3302-3314).
2.2.1. Bayesian Optimal Phase 2 (BOP2) Design (Example)
In this example study, formal monitoring of safety and efficacy will be performed simultaneously after the
first 9 subjects in cohorts of size 3 using the Bayesian optimal phase 2 (BOP2) design (Zhou, Lee and
Yuan, 2017). A maximum of 30 subjects will be enrolled and the efficacy endpoint is the ORR and safety
endpoint is DLT rate:
We will simultaneously monitor efficacy and safety endpoints. Specifically, let 𝑛 denote the interim sample
size and 𝑁 denote the maximum sample size. Let 𝑌"## and 𝑌$%& respectively denote the efficacy and toxic
endpoints, with 𝑌"## = 1 and 𝑌$%& = 1 respectively indicating that subjects experience efficacy and
toxicity. Let 𝑝"## = 𝑃𝑟(𝑌' = 1), 𝑝$%& = 𝑃𝑟(𝑌( = 1) and define the null hypothesis 𝐻) : 𝑝"## ≤ 0.1 and 𝑝$%& >
0.25, representing that the treatment is inefficacious or overly toxic. We will stop enrolling subjects and
claim that the treatment combination is not promising if
𝑛
𝑃𝑟(𝑝"## > 0.1|𝑑𝑎𝑡𝑎) < 𝜆( )* ,
𝑁
or
𝑛
𝑃𝑟(𝑝$%& ≤ 0.25|𝑑𝑎𝑡𝑎) < 𝜆( )* ,
𝑁
where 𝜆=0.65 and 𝛼=0.9 are design parameters optimized to minimize the chance of incorrectly claiming
that an efficacious and safe treatment is unacceptable (i.e., type II error) under the alternative hypothesis
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𝐻' : 𝑝"## = 0.25 and 𝑝$%& = 0.1, while controlling the type I error rate at 0.05 (i.e., the chance of incorrectly
claiming that an inefficacious or overly toxic treatment is acceptable is no more than 5%). Assuming a
Dirichlet prior distribution 𝐷𝑖𝑟(0.05,0.05,0.2,0.7) for the treatment effect, the above decision rule
corresponds to the following stopping boundaries and yields a statistical power of 0.8354 under 𝐻' :
Table 2: Optimized stopping boundaries
# Subjects treated Stop if # response ≤ OR # toxicity ≥
12
0
5
15

1

5

18

1

6

21

2

6

24
27

2
3

6
7

30

3

7

Based on Table 2, we will perform the interim analysis when the number of enrolled subjects reaches 12,
15, 18, 21, 24, 27. When the total number of subjects reaches the maximum sample size of 30, we will
reject the null hypothesis and conclude that the treatment combination is acceptable if the number of
responses in the efficacy endpoint are greater than 3, and the number of toxicities are less than 7;
otherwise we will conclude that the treatment combination is unacceptable.
Below are the operating characteristics of the design based on 10000 simulations using the BOP2 web
application, which is available at http://www.trialdesign.org.
Table 3: Operating characteristics
Pr(Eff) Pr(Tox) Pr(Eff & Tox) Early stopping (%) Claim acceptable (%) Sample size
0.10
0.10

0.10
0.25

0.05
0.05

80.60
93.87

18.92
4.90

18.9
16.3

0.10

0.40

0.05

99.56

0.24

13.5

0.25

0.10

0.05

15.76

83.54

27.9

0.25

0.25

0.05

65.70

27.69

21.7

0.25
0.40

0.40
0.10

0.05
0.05

97.45
4.12

1.22
95.09

14.8
29.5

0.40

0.25

0.05

62.23

30.45

22.5

0.40

0.40

0.05

97.03

1.54

14.9

3. Phase III Clinical Trials
Phase III trials compare a new drug to the standard-of-care drug. These trials assess the side effects of
each drug and which drug works better. Phase III trials enroll 100 or more subjects. Often, these trials
are randomized. This means that subjects are put into a treatment group, by chance. Randomization is
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needed to make sure that the people in all trial arms are alike. This ensures that the results of the clinical
trial are due to the treatment and not differences between the groups. In the US, when phase III clinical
trials (or sometimes phase II studies) show a new drug is more effective and/or safer than the current
standard-of-care drug, a new drug application (NDA) is submitted to the Food and Drug Administration
(FDA) for approval. The FDA then reviews the results from the clinical trials and other relevant
information. Based on the review, the FDA decides whether to approve the treatment for use in subjects
with the type of illness on which the drug was tested. If approved, the new treatment often becomes a
standard of care, and newer drugs must often be tested against it before being approved.
In many instances, some routine monitoring of trial progress, usually blinded to treatment allocation, is
often undertaken as part of a phase III trial. Such monitoring may be undertaken in conjunction with a
data and safety monitoring board (DSMB), established to review the information collected. It would
therefore appear that assessment of interim treatment differences is a logical and worthwhile extension.
However, the handling of treatment comparisons while a trial is still in progress poses problems in medical
ethics, statistical analysis and practical organization.
The most appealing reason for monitoring trial data for treatment differences is that, ethically, it is
desirable to terminate or change a trial when evidence has emerged that one treatment is clearly superior
to the other. This is particularly important when life-threatening diseases are involved. Alternatively, the
data may support the conclusion that the experimental treatment and the control do not differ by some
predetermined clinically relevant magnitude, in which case it would be desirable, both ethically and
economically, to stop the study and divert resources elsewhere. Finally, if information in a trial is accruing
more slowly than expected, perhaps because of a low event rate, then extension of recruitment until a
large enough sample has been recruited may be appropriate.
However, multiple analyses of accumulating data lead to problems in the interpretation of results. The
main problem occurs when significance testing is undertaken at the various interim looks. Even if the
treatments are really equally effective, the more often one analyzes the accumulating data, the greater
the chance of eventually and wrongly detecting a difference, thereby drawing incorrect conclusions from
the trial.
A second problem concerns the final analysis. When data are inspected at interim looks, the analysis
appropriate for fixed sample size studies is no longer valid. Quantities such as P values, point estimates
and confidence intervals are still well defined, but new methods of calculation are required. If a traditional
analysis is performed at the end of a trial that stops because the experimental treatment is found better
than control, the P value will be too small (too significant), the point estimate too large and the confidence
interval too narrow. To remedy these problems, special techniques are required. These can be broadly
termed sequential methods.
A sequential test monitors a statistic summarizing the current difference between the experimental
treatment and control at a series of times during the trial. If the value of this statistic crosses some
specified critical value (i.e., stopping rule or boundary), the trial is stopped and an appropriate conclusion
drawn. It is possible to look after every subject or to have just one or two interim analyses. If the statistic
stays within the test boundary then there is not enough evidence to come to a conclusion at present and
a further interim look should be taken. It is the details of the derivation of the stopping rule that introduces
much of the variety of sequential methodology. Key early work in the area includes the tests of Pocock
and O'Brien & Fleming. A more flexible approach, referred to as the alpha-spending method was
proposed by Lan & DeMets and extended by Kim & DeMets.
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3.1.

Sequential Design – Example

A sample size of 40 subjects will be randomized 1:1 to Drug A or control. Assume the control arm’s true
median PFS will be approximately 4 months. Assume median PFS in the Drug A arm will be 8.5 months,
corresponding to a hazard ratio of 0.471 (Drug A vs. control). The study is anticipated to finish accrual
at 36 months with an additional 6 months follow up for a total study duration of 42 months. Under these
conditions, we will have 80% power using a 1-sided log rank test with type I error of 0.10. Uniform accrual
and exponential PFS distributions are assumed and the expected total PFS event count is 34. We will
have an interim look for futility once half the expected events (17 events) are observed. A Lan-Demets
spending function using an Obrien-Flemming boundary will be used for futility stopping boundaries. We
will stop for futility at our interim look if our p-value is greater than 0.470.

4. Phase IV Clinical Trials (Post Marketing)
Drugs approved by the FDA are often watched over a long period of time in phase IV studies. Even after
testing a new medicine on thousands of people, the full effects of the treatment may not be known. Some
questions may still need to be answered. For example, a drug may get FDA approval because it was
shown to reduce the risk of cancer coming back after treatment. But does this mean that those who get
it are more likely to live longer? Are there rare side effects that haven’t been seen yet, or side effects that
only show up after a person has taken the drug for a long time? These types of questions may take many
more years to answer, and are often addressed in phase IV clinical trials. These studies may also look
at other aspects of the treatment, such as quality of life or cost effectiveness.
5. Pilot Studies
Pilot studies represent a fundamental phase of the research process. The purpose of conducting a pilot
study is to examine the feasibility of an approach that is intended to be used in a larger scale/main study.
A pilot study can be used to evaluate the feasibility of recruitment, randomization, retention, assessment
procedures, new methods, and implementation of the novel intervention.
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Conducting a pilot study prior to the main study can enhance the likelihood of success of the larger scale
study and potentially help to avoid doomed main studies. Pilot studies should be well designed with clear
feasibility objectives, clear analytic plans, and explicit criteria for determining success of feasibility. They
should be used cautiously for determining treatment effects and variance estimates for power or sample
size calculations. Finally, they should be scrutinized the same way as full-scale studies.
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OBSERVATIONAL STUDIES
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1.

Cohort Studies

In cohort studies, participants that have a particular common exposure (the cohort) are identified and
outcomes are observed over time. In these studies, information about the risk factor or exposure is
determined prior to the observation of the outcomes. Cohort studies can either be prospective or
retrospective.
1.1.

Prospective Cohort Studies

In prospective cohort studies, the risk factor or exposure and subsequent outcomes are observed after
the beginning of the study. This is also known as a longitudinal study. The selection of participants is
influenced by a variety of factors, including the type of exposure being investigated, the frequency of the
exposure in the population, and the accessibility of participants, as well as the likelihood of their
continuing participation. Unexposed participants should be sampled from the same (or comparable)
source population as the exposed group. Both exposed and unexposed groups should not have the
outcome being investigated and be equally susceptible to development of the outcome at the beginning
of the study. The baseline characteristics of the exposed group should not differ systematically from those
in the unexposed group for the exposure of interest. Equivalent information should be available on
exposure and outcomes in both groups. Both groups should be accessible and available for follow-up.
1.2.

Retrospective Cohort Studies

Retrospective cohort studies, sometimes called “chart reviews”, are carried out at the present time and
look to the past to examine medical events or outcomes. Specifically, a cohort of participants selected
based on exposure status is chosen at the present time, and outcome data (e.g. disease status, event
status), which was measured in the past, are reconstructed for analysis. The primary disadvantage of
this study design is the limited control the investigator has over data collection. The existing data may be
incomplete, inaccurate, or inconsistently measured between participants. However, because of the
immediate availability of the data, this study design is comparatively less costly and shorter than
prospective studies and can provide valuable results to address important clinical research questions.
Comparing effectiveness of interventions in retrospective studies is difficult because usually there are
baseline differences between interventions. In randomized controlled trials (RCTs), treatment influences on
outcomes are usually considered as causal because the participants taking different treatments are
supposed to be exchangeable (i.e., their characteristics, except the intervention that is evaluated, are
expected to be the same). However, in retrospective studies the assumption of exchangeability is not valid
because participants are prescribed different medications precisely because they differ in prognostic factors.
Hence, applying sound statistical methods to reduce confounding – a systematic error in a study that results
from confusing the effect of the exposure of interest with other associated correlates of the outcome – is
needed when analyzing retrospective studies. Propensity scores are a suitable methodology for adjusting
for such differences and, therefore, for obtaining unbiased effectiveness estimates. The goal of propensity
scores is to balance observed covariates between participants from the treatment groups in order to mimic
what happens in an RCT.
In a balanced two-arm randomized trial, the propensity score of each subject is equal to 1/2 for every
covariate (i.e., subjects with different observed covariates have the same probability of receiving treatment,
and reversibly each possible value of the observed covariates is as likely to occur in either of the two groups.)
Typically, in retrospective studies there are participants that are more likely to receive an aggressive
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treatment because of some of the pre-treatment characteristics included in the observed covariates.
Analogously, other participants are more likely to receive a less aggressive treatment given their covariates.
However, suppose that we compare two participants who have the same propensity score. These
participants could be different in terms of their observed covariates. What is important is that these
differences cannot predict which participant has more chance of receiving the aggressive treatment. Given
their observed covariates, both have the same probability to be treated despite being quite different in terms
of their covariates. Hence, if participants with the same propensity scores are grouped, both aggressively
treated and less aggressively treated participants in these groups will have on average covariate patterns
similar to those that would occur in a randomized trial.
2.

Case-Control Studies

In case-control designs, participants are identified by whether or not they have the outcome of interest.
Then a comparison of the groups with respect to exposures or some other attribute is made. These
studies begin with case and control participants (i.e., the outcome of interest is known) and look back
retrospectively at the participants’ exposures to find an association. One of the first steps in this design
is to identify and select cases. Case identification should be very specific and the source population
should be well defined. The criteria for a case should minimize the likelihood that true cases are missed,
while simultaneously avoiding falsely classifying a nonaffected participant as a case. The next key step
is to identify and select controls. Ideally, controls are chosen at random from the source population. The
selected control group must be at similar risk of developing the outcome.
In addition to confounding being an issue in observational studies, selection bias is also a danger to the
internal validity of observational studies; and this bias poses a particular threat to case-control studies.
Selection bias occurs when there is a different probability of an participant being chosen to participate in
a study or assigned to an intervention, and the characteristics of that participant are confounded with
outcomes. Removing biases are central methodological issues in observational studies, therefore,
applying sound statistical techniques to address these issues is essential. Ignoring these biases often
results in incorrect estimates of the association or effect of the intervention. Of note, selection bias and
confounding are not affected by sample size. While large sample sizes provide real advantages in the
accurate and powerful detection of associations, their ability to identify causality is not as strong. Indeed,
with a very large sample size, a small effect estimate can yield a very low p-value, making many claim
cause and effect. Study design can be much more important than p-values in this context. No amount of
elaborate statistical analysis can help an experiment that was conducted without attention to key issues
such as study design, potential sources of variation, and confounding. Thus, study design and statistical
analysis should go hand in hand.
3.

Cross-Sectional Studies

In cross-sectional studies, the exposure and outcome information is assessed simultaneously at a single
point in time. Unlike in cohort studies (participants selected based on exposure) or case-control studies
(participants selected based on outcome), the participants in a cross-sectional study are merely selected
based on the inclusion and exclusion criteria set for the study. These designs are often used for
population-based surveys and to assess the prevalence of diseases in clinic-based samples. Since
cross-sectional studies are a one-time measurement of exposure and outcome, it is difficult to derive
causal relationships from the analysis. However, the investigator can study the association between
these measures. Cross-sectional studies can typically be conducted relatively fast and are inexpensive.
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They may be useful for public health planning, monitoring, and evaluation. For example, the National
AIDS Programme may conduct cross-sectional sentinel surveys among high-risk groups and ante-natal
mothers every year to monitor the prevalence of HIV in these groups.
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DATA QUALITY
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Investigators seeking statistical analyses for their research should meet with the statistician
prior to any data collection.
The following are the four approved MDACC databases: REDCap (Research Electronic Data
Capture), Prometheus, DMI, MOCLIP
Excel Spreadsheets
Data that require relabeling or editing may prolong the time required to complete the statistical analyses.
If data are not correctly entered or coded, inaccurate or incomplete analyses may result. The following
is a list of suggested data considerations that may minimize the time required to organize and prepare
data for statistical analysis.
1. Each row should have a unique identifier to keep track of which data correspond with a given subject
or other experimental unit. Preferably, this identifier will be recorded in the first column. This identifier
will typically be a medical record number (MRN) or accession number but may be another identifier.
A unique identifier is required so that data queries can be resolved and also so that data may be
merged between different datasets, if necessary.
2. Each column should contain only one type of data. Dates, text, and numbers are different types of
data.
For example, if a column contains lab values, as well as entries such as “N/A”, “<0.1”, “could not be
determined”, “undetectable”, or “>1000000”, the data may be more difficult to process. For example,
including the “>” symbol in one cell of the column will cause a statistical analysis program to read in
an entire column as text rather than as numeric values.
3. Each column should contain only one piece of data (i.e., one variable).
For example, systolic and diastolic blood pressure should be recorded in two separate columns.
Instead of entering “144/88” in one column, the systolic pressure of 144 should be recorded in one
column and the diastolic pressure of 88 in another.
4. Columns of data should not include units. If units are necessary, the units should be recorded in a
separate column or in the column header. For example, if some weights are measured in kilograms
and some in pounds, the units of measurement should be entered into the next column. If all entries
in the same column are based on the same unit, the unit of measure may be noted in the column
header.
5. Coding should be consistent. Multiple spellings and variable lengths must be reconciled prior to
analysis.
For instance, “male”, “Male”, “m”, “ M” and “M” are all different to the computer software and must
be coded consistently prior to analysis.
6. The use of Protected Health Information (PHI) should be kept to a minimum and on a need-to-know
basis. PHI includes the following information:
1. Subject names
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2. All geographical subdivisions smaller than a State, including street address, city, county,
precinct, zip code, and their equivalent geocodes, except for the initial three digits of a zip
code, if according to the current publicly available data from the Bureau of the Census: (1)
The geographic unit formed by combining all zip codes with the same three initial digits
contains more than 20,000 people; and (2) The initial three digits of a zip code for all such
geographic units containing 20,000 or fewer people is changed to 000.
3. All elements of dates (except year) for dates directly related to an individual, including birth
date, admission date, discharge date, date of death; and all ages over 89 and all elements of
dates (including year) indicative of such age, except that such ages and elements may be
aggregated into a single category of age 90 or old
4. Phone numbers
5. Fax numbers
6. Electronic mail addresses
7. Social Security numbers
8. Medical record numbers
9. Health plan beneficiary numbers
10. Account numbers
11. Certificate/license numbers
12. Vehicle identifiers and serial numbers, including license plate numbers
13. Device identifiers and serial numbers
14. Web Universal Resource Locators (URLs)
15. Internet Protocol (IP) address numbers
16. Biometric identifiers, including finger and voice prints
17. Full face photographic images and any comparable images
18. Any other unique identifying number, characteristic, or code (note this does not mean the
unique code assigned by the investigator to code the data)
Per institutional policy ADM0335 Information Security Office Policy for the Use and Protection of
Information Resources, PHI should NOT be sent outside MD Anderson (i.e., PHI should not be sent
to/from non-MDACC email accounts). In general, DO NOT SEND SUBJECT NAMES to the statistician.
7. Records should be sorted carefully or not sorted at all.
Excel has the capability of sorting a column independent of other columns. This means that it is
extremely easy to completely scramble the data in a spreadsheet.
8. A key or “Data Dictionary” to define variables and describe possible values for variables should be
provided.
For example, a separate coding sheet should be provided detailing that the column named “N”
indicates “Nodal status”, where value 0 corresponds to “negative” status and values 1-3 correspond
to “positive” status.
9. Colored cells or colored text should not be used to convey information. Separate columns should be
used instead.
For example, to denote different subject groups, use a separate column with a number or letter to
identify each group and include this information in the data dictionary (A=group 1, B=group 2, etc.).
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10. Empty cells should not be used to convey meaningful information, such as the lack of a condition. In
general, if data are missing for only one possible reason, empty cells can be used to indicate missing
data. However, if it’s desirable or necessary to distinguish between different reasons for a missing
data value, separate codes or database fields should be used to distinguish between these types.
For example,
•
•
•
•

Unknown values
Values that are not applicable
Not done
Not recorded

11. Values below the limit of detection for an assay should not be listed as missing/unknown. Instead,
the statistician should be consulted as to the appropriate manner to record these data.
12. Data field or variable names should be short, meaningful and unique. Names exceeding two words
should be avoided. The length of the name should be within 12 characters. Symbols such as ‘/’, ‘&’
‘( )’, ‘?’, etc. should be avoided. Variable names may include numbers but cannot begin with a
number.
13. The variable names should be presented in the first row of the spreadsheet as the header for each
column. The other rows, beginning with row number 2 should contain the data values for each
experimental unit (i.e., one row per subject).
14. Cells should not be merged.
15. Cells should not be hidden.
16. The header row should not be duplicated down in the spreadsheet.
17. Summary statistics should not be included in the same spreadsheet as the raw data. Summary
statistics or results of preliminary statistical testing may be useful for reference, but these should not
be placed in the same spreadsheet as the raw data. Such results should be located in a separate
spreadsheet or document, if necessary.
18. For time intervals, start and end dates must be provided rather than a computed interval.
For example, for survival calculations, the start date as well as the death date or last follow-up date
are required, not simply a calculation of time.
Examples of a less than ideal dataset and a better version of the same dataset are displayed below:
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“Bad” Example Data Set:

The above example violates data considerations #3, 4, 5, 6, 10, 17 and 18.

“Better” Example Data Set:
Death
ID Group DOB
Sex Race Status Date
Creatinine SBP
1
1 08/19/1955
M
1
0
123
2
1 04/23/1953
F
1
1 06/12/2008
0.4 125
3
1 10/31/1942
M
2
0
0.8 127
4
0 05/06/1970
M
2
0
116
5
0 11/12/1932
F
3
1 01/12/2009
2 115
6
0 08/09/1952
F
1 09/25/2007
1.8 114
Key
Group 1 = Treatment
Group 0 = Control
Status 1 = Dead
Status 0 = Alive
Creatinine units = mg/dL
Race 1 = Black
Race 2 = White
Race 3 = Arab

DOB = Date of Birth
SBP = Systolic Blood Pressure
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STATISTICAL METHODOLOGY
CATEGORICAL MEASURES
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1. Analysis of Categorical Measures
Categorical data analysis is concerned with the analysis of categorical measures (e.g., response), regardless
of whether any accompanying explanatory variables are also categorical or are continuous. An important
consideration in determining the appropriate analysis of categorical variables is their scale of measurement.
The scale of measurement of a categorical variable is a key element in choosing an appropriate analysis
strategy. By taking advantage of the methodologies available for the particular scale of measurement, a
well-targeted strategy can be chosen. If the scale of measurement is not taken into account, an inappropriate
strategy may be chosen that could lead to erroneous conclusions. Categorical variables can be a) nominal;
b) dichotomous; and c) ordinal.
•

•
•

Nominal variables are variables that have two or more categories, but which do not have an
intrinsic order (e.g., red, blue, green, yellow). Of note, the different categories of a nominal
variable can also be referred to as groups or levels of the nominal variable.
Dichotomous variables are nominal variables which have only two categories or levels (e.g.,
male, female)
Ordinal variables are variables that have two or more categories just like nominal variables only
the categories can also be ordered or ranked (e.g., low, medium, high).

1.1. Dichotomous Variables
Dichotomous variables are those that have two possible outcomes (e.g., response vs. no response). The 2
x 2 contingency table (see Table 1) is one of the most common ways to summarize categorical data.
Generally, interest lies in whether there is an association between the row variable (Response at Day 90)
and the column variable (Treatment). The question of interest in this example is whether the PR or better
response rates for Bu-Mel treatment (102/104; 98%) and Mel treatment (95/98; 97%) are the same.
Table 1. Association between Treatment and Response
Treatment
Response at Day 90
PR or better
SD/PD
Total

Total

Bu-Mel

Mel

102

95

197

2

3

5

104

98

202

The null hypothesis (i.e., H0) for this illustration is: There is no association between treatment and response
at Day 90. If the sample size in each cell is large enough, the statistic that is used to test the hypothesis is
based on the chi-square statistic. However, if the counts in the table are too small to meet the sample size
requirements necessary for the chi-square distribution to apply (rule of thumb: < 5 in any cell), exact methods
are used to test the hypothesis of no association. Since the number of subjects with SD/PD is < 5 is in two
cells in our example, an exact method should be employed.
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Fisher’s Exact Test
If we assume the margins of the 2 x 2 contingency table are fixed (i.e., 104, 98, 197, 5) then the significance
level (i.e., p-value) is the probability of the observed data or more extreme data occurring under the null
hypothesis. The two-sided Fisher’s exact p-value in our example is 0.675.

Measures of Association
Measures of association are used to assess the strength of an association. For the 2 x 2 contingency table,
one measure of association is the odds ratio (OR).
For Table 1, the OR compares the odds of the Bu-Mel subjects having PR or better response to the odds of
the Mel subjects having PR or better response. It is computed as:
OR = 102/95 = 1.6
2/3
The OR ranges from 0 to infinity. When the OR is 1, there is no association between the two variables. If
the OR is greater than 1, the Bu-Mel group is more likely than the Mel group to have PR or better response.
If the OR is less than 1, then Bu-Mel is less likely than the Mel group to have PR or better response.

Another measure of association is relative risk, which is the risk of developing a particular condition (e.g.,
cancer) for one group compared with another group. In our example, the relative risk is computed as:
RR = 102/197 = 0.518 = 1.3
2/5
0.4
1.2. Logistic Regression Modeling

In general, the overall idea of regression modeling is to examine two things: (1) does a set of
predictor (explanatory) variables do a good job in predicting an outcome (dependent) variable? (2)
Which variables in particular are significant predictors of the outcome variable, and in what way do
they–indicated by the magnitude and sign of the beta estimates–impact the outcome
variable? These regression estimates are used to explain the relationship between one dependent
variable and one or more independent variables.
Logistic regression is a form of statistical modeling that describes the relationship between a categorical
variable and a set of explanatory variables. The explanatory variables can be categorical or continuous.
One of the advantages of logistic regression modeling is that model interpretation is possible through odds
ratios, which are functions of model parameters.
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Example: Is there an association between treatment and progression/death adjusting for age (65 years; >
65 years), cytogenetic risk (high; standard), and R-ISS stage (I-II; III)?

Measure

Odds Ratio (95% CI)

p-value

Bu-Mel vs. Mel

0.77 (0.37, 1.59)

0.48

> 65 years vs. 65 years

0.97 (0.39, 2.38)

0.94

High vs. standard

0.73 (0.29, 1.82)

0.50

III vs. I-II

1.85 (0.73, 4.71)

0.20

Interpretation: In addition to the p-values being large, the odds ratios for each measure is close to 1 and the
95% confidence interval contains 1, indicating that none of the measures were significantly associated with
progression and/or death.

Reference
Stokes, M.E., Davis, C.S., and Koch, G.G., Categorical Data Analysis Using the SAS System, Cary,
NC: SAS Institute Inc., 1995.
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STATISTICAL METHODOLOGY
CONTINUOUS MEASURES
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1. Continuous Measures
Continuous variables are also known as quantitative variables and can be categorized as either interval
or ratio variables.
•

•

Interval variables are variables for which their central characteristic is that they can be measured
along a continuum and they have a numerical value (e.g., temperature). So the difference
between 20°C and 30°C is the same as 30°C to 40°C.
Ratio variables are interval variables, but with the added condition that 0 (zero) of the
measurement indicates that there is none of that variable. So, temperature measured in degrees
Celsius is not a ratio variable because 0°C does not mean there is no temperature. However,
temperature measured in Kelvin is a ratio variable as 0° Kelvin (often called absolute zero)
indicates that there is no temperature whatsoever.

It has been observed that the natural variation of many continuous variables tends to follow a bell-shaped
distribution, with most values clustered symmetrically near the mean and a few values falling out on the tails.
The bell-shaped distribution is also known as the normal (or Gaussian). The shape and location of a normal
distribution are completely determined by its mean and standard deviation (SD). In a normal distribution,
68% of the data fall within 1 SD of the mean (34% above, 34% below); 95% within 2 SD and 99.7% within 3
SD of the mean (see figure). For non-Gaussian distributions, the SD does not describe a known proportion
of the observations.

2. Analysis of Continuous Measures
Analyses of continuous measures fall into two broad classifications of statistical procedures; parametric
and non-parametric. Parametric analyses have the following assumptions about the underlying data: i.) the
data were derived from a population in which the characteristic to be studied is normally distributed; ii.)
the variances within the groups to be studied must be homogeneous; and iii.) the data are independent.
These assumptions should be confirmed or assumed with good reason when using these tests. If these
assumptions are violated, the resulting statistics and conclusions will not be valid, and the tests may lack
power relative to alternative tests. Non-parametric tests are sometimes called distribution-free
tests because they are based on fewer assumptions (e.g., they do not assume that the outcome is
approximately normally distributed). These tests assume that the underlying distributions have the same
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shape and spread. The cost of fewer assumptions is that non-parametric tests are generally less powerful
than their parametric counterparts (i.e., when the alternative is true, they may be less likely to reject H0).
The following table presents parametric tests and their non-parametric counterparts for specific types of
analyses of continuous variable. For example: Say you were interested in evaluating whether a particular
diet was effective, you could test the change in a person’s weight from baseline to 6 months to determine if
it was significantly different from 0 (i.e., no change) using either a paired t-test or Wilcoxon signed-rank test.

Analysis Type
Compare quantitative measure between
two distinct/independent groups
Compare two quantitative
measurements taken from the same
individual
Compare quantitative measurements
between three or more
distinct/independent groups
Estimate the degree of association
between two quantitative variables

2.1.

Parametric Test

Non-parametric Test

Two-sample t-test

Wilcoxon rank-sum test

Paired t-test

Wilcoxon signed-rank
test

Analysis of variance (ANOVA)

Kruskal-Wallis test

Pearson coefficient of correlation

Spearman’s rank
correlation

Linear Regression

In linear regression, both the dependent and independent measures are continuous. Linear regression
attempts to model the relationship between the dependent and independent measures by fitting a linear
equation to observed data. A linear regression line has an equation of the form Y = α + β X, where X is
the independent variable and Y is the dependent variable. The slope of the line is β and α is the intercept
(the value of y when x = 0).
Linear Regression Example: Is there an association between total number of radium doses and prostate
specific antigen (PSA), hemoglobin, and alkaline phosphatase (ALK)?
Measure

β

SE of β

95% LCI 95% UCI

p-value

Intercept

4.972

1.296

2.403

7.542

< 0.001

PSA

-0.000

0.000

-0.001

0.001

0.56

Hemoglobin

0.002

0.106

-0.208

0.212

0.99

ALK

-0.001

0.001

-0.002

0.001

0.45

Interpretation: In addition to the p-values being large, the slope, β, values are close to 0, indicating that
there’s no association between total number of radium doses and the independent factors.

Page 38 of 58

ANOVA Example: Is there an association between total number of radium doses and subjects with PSA >
10 ng/mL, hemoglobin < 10 g/dL, and ALK ≥ 146 U/I?
Measure

β

Intercept

5.187

0.286

4.620

5.754

< 0.001

PSA > 10 ng/mL

0.047

0.331

-0.610

0.704

0.89

Hemoglobin < 10 g/dL

0.001

0.423

-0.837

0.840

1.00

ALK ≥ 146 U/I

-0.973

0.317

-1.601

-0.345

0.003

Measure

SE of β 95% LCI 95% UCI

LS Means

SE

> 10 ng/mL

4.75

0.21

≤ 10 ng/mL

4.70

0.32

< 10 g/dL

4.73

0.38

≥ 10 g/dL

4.72

0.19

≥ 146 U/I

4.24

0.26

< 146 U/I

5.21

0.27

p-value

PSA

Hemoglobin

ALK

Interpretation: When the ALK measure is divided into two clinically meaning groups, a significant association
between total number of radium doses and ALK is observed. Subjects with ALK values ≥ 146 U/I received
significantly fewer radium doses (least square [LS] means: 4.24) compared with those with ALK values
< 146 U/I (LS means: 5.21). It may be more clinically meaningful to interpret these results using LS means
(adjusted means) as opposed to slopes.
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STATISTICAL METHODOLOGY
TIME-TO-EVENT/SURVIVAL MEASURES
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1. Analysis of Time-to-Event/Survival Measures
In many medical studies the outcome of interest is the length of time until an event occurs, i.e., the time
elapsed from one well-defined event, for example, start of treatment, to another well-defined event, for
example, death. For convenience, we will refer to this time as “survival time” and to the outcome as “death”,
even though the outcome may be some other, possibly favorable, event such as disease remission. The
distribution of survival times is most often described in terms of the survival function, S(t). This function is
defined for each time t as the probability that an individual survives longer than time t. The graph of S(t)
against time is called the survival curve. The distribution of survival times is also described in terms of the
hazard function, h(t). This function is defined as the probability that an individual dies during a short interval
of time given that the individual survived up to that interval.
Although survival time is a continuous variable, one cannot, in general, use standard analysis techniques for
continuous measures with survival data because of the presence of censored observations. Censored
observations arise in subjects for whom the critical event has not yet occurred at the time of the analysis.
Censored observations can arise if a subject is known to be alive when the analysis is carried out or is lost
to follow-up during the course of a study. The time to the last date the live subject was examined is known
as the censored survival time. Thus, the relevant response data for a survival analysis consists of two
components: (1) the subject’s status at the last follow-up observation (e.g., dead or alive) and (2) the length
of time the subject was followed. Special techniques have been developed to deal with censored survival
data which take in account the information provided by censored observations.
1.1.

Survival Function Estimation

The two most common methods for estimating the survival function in the presence of censored data are
the Kaplan-Meier product-limit method and the Cutler-Ederer (actuarial) life-table method. These are both
non-parametric methods which do not require specification of the functional form of the survival time
distribution (which is often unknown).
In the life-table method, survival times are grouped into convenient intervals. The probability of dying during
an interval is computed for each interval and the survival function is taken as the product of the survival
probabilities for succeeding intervals. This method assumes that censored observations are uniformly
distributed within each interval and that the risk of death is fairly constant within each interval. The productlimit can be considered as a special case of the life-table estimate where each interval contains only one
observation. In the Kaplan-Meier approach, the intervals are determined by the data and thus the results
are not dependent on the user’s choice of time intervals.
1.2.

Comparing Survival Distributions

If subjects are divided into groups according to treatment or prognosis, then the survival function can be
estimated for each group, and a test of equality of the survival functions across groups may be performed.
Because survival times are positively valued and often highly skewed, nonparametric tests are most often
used to make comparisons. In the absence of censoring, standard nonparametric tests could be used to
compare survival distributions, however, for censored data, special tests are needed. The tests most often
encountered are nonparametric linear rank tests: typically, the Mantel-Cox log-rank test, and the BreslowGehan generalized Kruskal-Wallis test. These tests accumulate weighted differences over time between
what is observed and what would have been expected under the null hypothesis of equivalence. Different
weights lead to different test statistics. Each test is sensitive to a characteristic pattern of difference between
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survival distributions being compared. Hence one should decide beforehand what pattern of difference is
most important clinically and select a significance test that has good statistical power for detecting differences
of that type. The Mantel-Cox test gives equal weight to all observations. The Breslow-Gehan test gives
greater weight to early observations, thus it is less sensitive than the Mantel-Cox test to late events when
few subjects remain in the study.
When interpreting the results of the statistical tests for comparing survival time distributions, consideration
should be given to the sample size of subjects used, and the pattern and amount of censoring. The number
of subjects is important, since the distribution of the test statistics and reported p-values are based on
asymptotic (large sample) statistical theory. Thus, ideally the test statistics are calculated using a large
sample of subjects. When only a small sample of subjects is used, the test results should be interpreted
with care.

Example: Is there a difference in progression-free survival between Bu-Mel and Mel subjects?

median

Number at risk
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Stratum 1: Bu-Mel
Product-Limit Survival Estimates
pfsmnths
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Product-Limit Survival Estimates
pfsmnths

Survival
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Product-Limit Survival Estimates
pfsmnths
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Survival
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Product-Limit Survival Estimates
pfsmnths

Survival
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Stratum 2: Mel

Quartile Estimates
Percent

Point
Estimate

95% Confidence Interval
Transform

[Lower

Upper)
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.

25
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13.4374 25.7248

Interpretation: Bu-Mel subjects experience significantly longer PFS median [95% CI] compared with their
Mel counterparts (64.7 [44.7, 64.7] vs. 43.5 [25.7, not estimated]; p=0.014).
Note: The difference between the median follow-up time and median OS results from subjects who were
alive at their last follow-up visit and how censoring is handled in computing Kaplan-Meier estimates. For
example, the median follow-up time for the Bu-Mel group was 22.6 months and for the Mel group was
20.2 months. If all subjects had died, then the median OS times would be the same as the median followup times.
1.3.

Cox Proportional Hazards Regression Modeling

Survival analysis methods can also be extended to assess several risk factors simultaneously, similar to
multiple linear and multiple logistic regression analysis. One of the most popular regression techniques
for survival analysis is Cox proportional hazards regression, which is used to relate one or several
independent factors, considered simultaneously, to survival time. In a Cox proportional hazards
regression model, the measure of effect is the hazard rate, which is the risk of failure (i.e., the risk or
probability of suffering the event of interest), given that the participant has survived up to a specific time.
There are several important assumptions for appropriate use of the Cox proportional hazards regression
model, including: i.) independence of survival times between distinct individuals in the sample; ii.) a
multiplicative relationship between the independent factors and the hazard (as opposed to a linear one
as was the case with multiple linear regression analysis); and iii.) a constant hazard ratio over time (i.e.,
proportional hazards). There are many advantages to the Cox model, one is its ability to include timedependent covariates, specifically those factors that can change after the start time (e.g., experiencing
acute GVHD after transplantation).

Example: Is there an association between treatment group and progression-free survival adjusting for age,
ethnicity, cytogenetic risk, ISS, response to induction therapy, and randomization algorithm?
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Measure
Bu-Mel vs. Mel

Hazard Ratio (95% CI)
0.57 (0.30, 1.10)

p-value
0.09

> 65 vs. ≤ 65 years of age

1.06 (0.48, 2.32)

0.89

High vs. Standard Cytogenetic Risk

1.29 (0.60, 2.78)

0.52

R-ISS Stage III vs. other

1.24 (0.58, 2.64)

0.58

PR or better to induction therapy vs.
worse than PR

0.58 (0.18, 1.91)

0.37

2nd vs. 1st Randomization Algorithm

2.33 (0.45, 12.19)

0.32

Interpretation: Adjusting for covariates, Bu-Mel subjects experienced a decreased risk of progression/death
compared with Mel subjects, however, this difference was not statistically significant at the 5% α-level.

1.4.

Competing Risks Analysis

Competing risks occur frequently in the analysis of survival data. A competing risk is an event whose
occurrence precludes the occurrence of the primary event of interest. For instance, in a study in which
the primary outcome is time to disease progression, death without disease progression would serve as
a competing event. A subject who dies is no longer at risk of progression. Regardless of how long the
duration of follow-up is extended, a subject will not be observed to progress once he or she has died.
Conventional statistical methods for the analysis of survival data assume that competing risks are absent.
Estimating the incidence of an event as a function of follow-up time provides important information on the
absolute risk of an event. In the absence of competing risks, the Kaplan-Meier estimate of the survival
function is frequently used for estimating the incidence function. One minus the Kaplan-Meier estimate
of the survival function provides an estimate of the cumulative incidence of events over time. However,
using the Kaplan-Meier estimate of the survival function to estimate the incidence function in the presence
of competing risks generally results in upward biases in the estimation of the incidence function. The
problem here is that the Kaplan-Meier estimator estimates the probability of the event of interest in the
absence of competing risks, which is generally larger than that in the presence of competing risks.
The Cumulative Incidence Function (CIF), as distinct from 1 – S(t), allows for estimation of the incidence
of the occurrence of an event while taking competing risks into account. This allows one to estimate
incidence in a population where all competing events must be accounted for in clinical decision making.
The cumulative incidence function for the kth cause is defined as: CIFk(t) = Pr(T ≤ t,D = k), where D is a
variable denoting the type of event that occurred. A key point is that, in the competing risks setting, only
1 event type can occur, such that the occurrence of 1 event precludes the subsequent occurrence of
other event types. The function CIFk(t) denotes the probability of experiencing the kth event before time
t and before the occurrence of a different type of event.
The CIF has the desirable property that the sum of the CIF estimates of the incidence of each of the
individual outcomes will equal the CIF estimates of the incidence of the composite outcome consisting of
all of the competing events. Unlike the survival function in the absence of competing risks, CIFk(t) will not
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necessarily approach unity as time becomes large, because of the occurrence of competing events that
preclude the occurrence of events of type k.
Example: Is there a difference in cumulative incidence of relapse, where death is a competing risk,
between Bu-Mel and Mel subjects?

Interpretation: The cumulative incidence relapse rate was significantly lower for Bu-Mel subjects compared
with Mel subjects (34% vs. 63%; p=0.003).

References
1. Allison, Paul D., Survival Analysis Using the SAS® System: A Practical Guide, Cary, NC: SAS
Institute Inc., 1995, 292 pp.
2. Austin, PC, Lee, DS, and Fine, JP. Introduction to the Analysis of Survival Data in the Presence
of Competing Risks. Circulation. 2016 Feb 9; 133(6): 601-609.

Page 49 of 58

STATISTICAL METHODOLOGY
BAYESIAN METHODS
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1. Bayesian Methods
The field of statistics exists because it is usually impossible to collect data from all individuals of interest
(population). Our only solution is to collect data from a subset (sample) of the individuals of interest, but
our real desire is to know the “truth” about the population. Quantities such as means, standard deviations
and proportions are all important values and are called “parameters” when we are talking about a
population. Since we usually cannot get data from the whole population, we cannot know the values of
the parameters for that population. We can, however, calculate estimates of these quantities for our
sample. When they are calculated from sample data, these quantities are called “statistics.” A statistic
estimates a parameter.
There are two schools of thought when it comes to statistical methodology; i.) frequentist view and ii.)
Bayesian view. The analysis methods described thus far represent the frequentist approach. When carrying
out statistical inference, that is, inferring statistical information from probabilistic systems, the two
approaches have very different philosophies.
Frequentist statistics assumes that probabilities are the frequency of particular random events occurring
in a long run of repeated trials. For example, as we roll a fair (i.e. unweighted) six-sided die repeatedly,
we would see that each number on the die tends to come up 1/6 of the time. Whereas, Bayesian inference
interprets probability as a measure of believability or confidence that an individual may possess about
the occurrence of a particular event. For example, we may have a prior belief about an event, but our
beliefs are likely to change when new evidence is brought to light. Bayesian statistics gives us a solid
mathematical means of incorporating our prior beliefs, and evidence, to produce new posterior beliefs.
Frequentist statistics tries to eliminate uncertainty by providing estimates. Bayesian statistics tries
to preserve and refine uncertainty by adjusting individual beliefs in light of new evidence.

The following table summarizes the differences between the frequentist and Bayesian approaches:
Frequentist
Parameters are fixed, but unknown
Data are random, until collected
After data are collected, the only
thing that is random is potential
future data based on repeated
sampling
Inferences are made conditional on
future, unobserved data

Bayesian
Parameters are unknown; therefore they
have a subjective probability distribution
Data are fixed once they are observed
Parameters are random
Inference are made conditional on the
current data and come from the posterior
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Bayes Theorem:
Pr(A | B) = Pr(B | A) Pr(A)
Pr(B)
Bayes Theorem: Fun Example
Scenario: You go to a friend’s party. 30% of his friends are Statisticians. You know that 70% of
Statisticians are Geeks and 10% of Non-Statisticians are Geeks. You meet a person who is clearly a
Geek. What is the probability s/he is a Statistician?
Pr(Statistician|Geek) = Pr(Geek|Statistician) x Pr(Statistician)
Pr (Geek)
Pr(S|G)

=

______ Pr(G|S) x Pr(S)___________
Pr(G|S) x Pr(S) + Pr(G|¬ S) x Pr(¬ S)

=

____.70 x .30____
.70 x .30 + .10 x .70

=

1.1.

.75

Bayesian Survival Analysis Example

Is there an association between treatment group and progression-free survival adjusting for age, ethnicity,
cytogenetic risk, ISS, response to induction therapy, and randomization algorithm?
Fitted Bayesian piecewise exponential survival time regression model for progression-free
survival time (N=157, number of events=39)

Measure Comparison
Bu-Mel vs. Mel

Mean of β
-0.572

Posterior Quantities
Posterior 95%
SD of β
Credible Interval
0.342
-1.258
0.077

Pr(β > 0 | Data)
0.045

> 65 vs. ≤ 65 years of age

-0.007

0.418

-0.826

0.795

0.513

High vs. Standard Cytogenetic Risk

0.200

0.395

-0.555

0.983

0.697

R-ISS Stage III vs. other

0.235

0.389

-0.563

0.957

0.730

-1.552

0.893

0.256

-2.055

1.289

0.397

PR or better to induction therapy vs.
-0.375
0.639
worse than PR
2nd vs. 1st Randomization Algorithm
-0.296
0.862
Bu-Mel vs. Mel Mean HR (95% HPD Interval) = 0.60 (0.25, 1.01).
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Posterior Probability =
0.955 that Busulfan +
Melphalan is Superior
to Melphalan Alone

Interpretation: The posterior probability that Bu-Mel is superior to Mel was 0.95 for PFS, adjusting for age,
ethnicity, cytogenetic risk, ISS, response to induction therapy, and randomization algorithm. The mean
hazard ratio (95% credible interval) was 0.60 (0.25, 1.01). [Reminder: The HR (95% CI) for Bu-Mel vs.
Mel from Cox model was 0.57 (0.30, 1.10).]

Reference
Bayesian Statistics: A Beginner’s Guide. QuantStart.Tutorial.
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MISCELLANEOUS
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1. What exactly is a p-value?
The p-value, or calculated probability, is the probability of finding the observed, or more extreme, results
when the null hypothesis (H0) of a study question is true – the definition of ‘extreme’ depends on how
the hypothesis is being tested. The null hypothesis is usually a hypothesis of "no difference" e.g. no
difference between two treatment groups. The null hypothesis for each study question should be clearly
defined before the start of your study. The alternative hypothesis (H1) is the opposite of the null
hypothesis; this is the hypothesis you set out to investigate. For example, question is "is there a significant
(not due to chance) difference in response between Bu-Mel and Mel alone?" and alternative hypothesis
is "there is a difference in response between Bu-Mel and Mel alone.”

The p-value computed can be from either a one-tailed statistical test (one-sided p-value) or a two-tailed
statistical test (two-sided p-value). If you are using a significance level of 0.05, a one-tailed test allots all
of the alpha to testing the statistical significance in the one direction of interest. This means that 0.05 is
in one tail of the distribution of your test statistic (see figure). When using a one-tailed test, you are testing
for the possibility of the relationship in one direction and completely disregarding the possibility of a
relationship in the other direction. Using the same significance level of 0.05, a two-tailed test allots half
of your alpha to testing the statistical significance in one direction and half of your alpha to testing
statistical significance in the other direction. This means that 0.025 is in each tail of the distribution of
your test statistic. When using a two-tailed test, regardless of the direction of the relationship you
hypothesize, you are testing for the possibility of the relationship in both directions. The only situation in
which you should use a one-sided p-value is when a large change in an unexpected direction would have
absolutely no relevance to your study. This situation is unusual; if you are in any doubt then use a twosided p-value.
The significance level (alpha [α]) is the probability of incorrectly rejecting the null hypothesis (type I error
or “false positive”) (see table below). The significance level (α) is used to refer to a pre-chosen probability
and the term "p-value" is used to indicate a probability that is computed after a given study. If the prespecified p-value is less than the chosen significance level (α), then you reject the null hypothesis (i.e.
accept that your sample gives reasonable evidence to support the alternative hypothesis). It does NOT
imply a "meaningful" or "important" difference; that is for you to decide when considering the real-world
relevance of your result. The choice of significance level at which you reject H0 is arbitrary.
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Conventionally, significance levels (α) of 5% (less than 1 in 20 chance of being wrong), 10% and 1%
have been used.

DECISION
TRUTH
Do Not Reject H0:
Reject H0:
H0 is true:
correct decision P
“false positive”
1- α
α (significance)
H0 is false:
“false negative”
correct decision P
β
1- β (power)
P = probability

The American Statistical Association’s statement on statistical significance and p-values:
1. P-values can indicate how incompatible the data are with a specified statistical model.
2. P-values do not measure the probability that the studied hypothesis is true, or the probability
that the data were produced by random chance alone.
3. Scientific conclusions and business or policy decisions should not be based only on whether
a p-value passes a specific threshold.
4. Proper inference requires full reporting and transparency.
5. A p-value, or statistical significance, does not measure the size of an effect or the importance of
a result.
6. By itself, a p-value does not provide a good measure of evidence regarding a model or
hypothesis.
Good statistical practice, as an essential component of good scientific practice, emphasizes principles
of good study design and conduct, a variety of numerical and graphical summaries of data,
understanding of the phenomenon under study, interpretation of results in context, complete reporting
and proper logical and quantitative understanding of what data summaries mean. No single index
should substitute for scientific reasoning.
1.1.

Multiple Comparisons

A scientific conclusion is always drawn from the statistical testing of hypothesis, in which the chosen
significance level (α), is used for decision-making. However, the probability of committing false statistical
inferences is considerably increased when more than one hypothesis is simultaneously tested (namely
the multiple comparisons), which therefore requires proper adjustment. In statistical inference, a p-value
is directly or indirectly computed for each hypothesis and then compared with the pre-specified
significance level (α) for determining if the H0 should be rejected or not. Therefore, there are two ways
for adjusting the statistical inference of multiple comparisons. First, it could directly adjust the observed
p-value for each hypothesis and keep the pre-specified significance level (α) unchanging; and this is
referred to as the adjusted p-value (e.g., analysis). Second, an adjusted cut-off corresponding to the

Page 56 of 58

initially pre-specified (α) could be computationally determined and then compared with the observed pvalue for statistical inference (e.g., sample size/power computation).
In the ideal world, we would be able to define a "perfectly" random sample, the most appropriate test and
one definitive conclusion. We simply cannot. What we can do is try to optimize all stages of our research
to minimize sources of uncertainty.
2. Confidence Intervals
The p-value, which is the final common pathway for nearly all statistical tests, conveys no information about
the extent to which two groups differ or two variables are associated. P-values, therefore, are not good
measures of the strength of the relation between study variables. By choosing a measure that quantifies the
degree of association or effect in the data and then calculating a confidence interval, researchers can
summarize the strength of association in their data and allow for random variation in a simple and
unambiguous way.
The statement that "the difference between treatments is not statistically significant (p>0.05)” amounts to a
statement that the trial results are consistent with there being no difference between treatments and is not
at all the same as saying that there is actually no difference. Confidence limits can advance our
understanding; the width of the interval is a guide to how precisely or sensitively a parameter of interest can
be estimated.
In statistical terms, the confidence interval means that if a series of identical studies were carried out
repeatedly on different samples from the same populations and a 95% confidence interval was calculated in
each study, then, in the long run, 95% of these confidence intervals would include the population value, thus,
(in simpler and less exact terms) "there is a 95% chance that the indicated range includes the true population
value”].
The general form for a confidence interval is:
estimate + (factor related to confidence level) x (standard error of the estimate).
A single study usually gives an imprecise sample estimate of the overall population value of interest. This
imprecision is indicated by the width of the confidence interval: the wider the interval the less precision. The
width depends essentially on three factors. Firstly, the sample size: large sample sizes will give more
precise results with narrower confidence intervals. In particular, wide confidence intervals emphasize the
unreliability of conclusions based on small samples. Secondly, the variability of the characteristic being
studied: the less variable it is, the more precise the sample estimate and the narrower the confidence
interval. Thirdly, the degree of confidence required: the more confidence the wider the interval.
It should clearly be understood that a difference which is statistically significant may or may not be
clinically relevant and a difference which is statistically non-significant does not necessarily imply
a clinically unimportant finding. Calculating confidence intervals is an effective tool in providing
information which can readily be interpreted clinically since it quantifies the magnitude of the differences
directly on the scale in which the data were measured or determined.
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3. Univariate vs. Multivariate vs. Multivariable
Univariate analysis refers to statistical methods that explore the relationship between one dependent
variable and one independent variable:
Example Model:

Response
=
Treatment
(dependent variable) (independent variable)

Multivariable analysis (or multiple regression) refers to statistical methods that explore the relationship
between one dependent variable and more than one independent variable:
Example Model:

Response
=
(dependent variable)

Treatment + Gender + Age + Disease Status
(independent variables)

Multivariate analysis refers to a broad category of statistical methods used when more than one dependent
variable at a time is analyzed for a subject. In multivariate analysis, models that predict a vector of responses
for each observation can be fit simultaneously.
Example Model:

Response, Toxicity
(dependent variables)

=

Treatment + Gender + Age + Disease Status
(independent variables)
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